Reflections of a Fireside Chat from the World Orphan Drug Congress 2020
September 9, 2020 |
Hear from Trish Shepherd COO, Patient & Brand Communications, OPEN Health
From junior doctor to gene therapy CEO, how one person’s drive to make rare disease curable is shaping the future of medicine.
It was a truly touching story to hear Dr Gaspar recant his early days working with young, severely immunocompromised patients at Great Ormond Street. Dr Gaspar knew that most of his patients would die within their first year without any therapy. Although bone marrow transplantation was an option for some patients, it was not without risk of complications.
THE POWER OF ONE
Dr Gaspar was first told of a single patient candidate for gene therapy while doing his rounds in 1993. He was initially convinced it was a Senior Doctor prank on a trainee, but as the years passed Dr. Gaspar saw that one patient return to the hospital with a fully healthy immune system and he was inspired to return to the lab to explore. And he did. In 2001, he went on to test the innovations he and his colleague were exploring in human clinical trials. The success these approaches received garnered much interest: first beyond the academic setting and then across regions and continents. The next step was clear – a commercial entity was needed to deliver more solutions to more people.
The result was Orchard Therapeutics, a company dedicated to setting up a process that enables the treatment cells to travel so that patients, who are already living with debilitating diseases, do not have to. As a business, Orchard Therapeutics want to introduce as many therapies as possible and, in order to enable a broader reach, are eager to work with regulators to explore reimbursement models from single payments, to annualised payments or payment by results.
AN UNBEATABLE MOMENT
When asked what it is like as a clinician to see this level of success, Dr Gaspar replies that there is nothing more rewarding than treating a patient with a therapy that you have created – it is, truly, an unbeatable moment.
Dr Gaspar has now moved on from his clinical duties to focus fully on his CEO responsibilities at Orchard Therapeutics, but remains certain that the options for clinicians when faced with rare genetic disease diagnoses, such as Severe Combined Immune Deficiency (SKID) and Metachromatic leukodystrophy (MLD), are different. The conversations with the families of patients will be entirely more positive in light of the new available options. The face of the disease is, thanks to Dr Gaspar and his colleagues’ work, now permanently changing for the better.
From this fireside chat, you can see the desire to introduce more curative therapies still burns bright.
DISCOVERING THE MOMENTS THAT MATTER MOST TO PATIENTS AND FAMILIES
Here at OPEN Health Patient & Brand Communications we pride ourselves on our deep understanding of the patient experience in rare disease and have significant expertise in consulting on the delivery of innovative treatments in complex treatment pathways, as well as providing niche patient support platforms to help patients and their families better understand novel treatments.
If you’d like to learn more, we’d love to hear from you and look forward to working together to help introduce more novel therapies to the people that need them most.
Trish Shepherd
COO, Patient & Brand Communications
This content was provided by OPEN Health
Company Details
Latest Content from OPEN Health
“New models” for agency pitching. My “Top takeaways” from the PM Society event
Paul Morrissey, Global Business Director, OPEN Health
Mapping the clinical and emotional journey to better understand lived experience
Written by OPEN Health's Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew
Delivering Medical Communications when travel is restricted: solving the 6 most common problems
Louise Carrington and Gemma Allen, OPEN Health
13th Edition – Spring MEDAFFAIRS Leaders Forum
OPEN VIE (Amanda Pulfer, Strategic Director and Sergio Diaz, Patient Centred Outcomes Consultant) were delighted to speak at the Medical Affairs Leaders Forum yesterday.
Keeping calm and carrying on: COVID-19 and approaches to CME/CPD during a viral outbreak
Celeste Kolanko, Managing Director, Liberum OPEN Health
Meet two of OPEN Health’s practices – Peloton Advantage and Pharmerit at MAPS 2020
Turning scientific knowledge and data into evidence
My Dad was ‘one in a million’, as the saying goes. But actually he was one in 300 million (of patients worldwide with rare disease)
Emily Wigginton, Client Services Director, OPEN Health Patient & Brand Communications
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes.
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications
CSR ‘Christmas Spirit’ 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts